Morgan Stanley analyst Terence Flynn reiterates Eli Lilly (NYSE:LLY) with a Overweight and maintains $1106 price target.
Morgan Stanley Reiterates Overweight on Eli Lilly, Maintains $1106 Price Target
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.